Nexentis Technologies Inc. (NXTS): Total Liabilities
$4.67M
As of 2025-12-31
$16.91M
As of 2026-06-30
+83.6%
3-year compound annual growth
+32.3%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $4.67M | +424.1% | 2026-03-31, Balance as of period end |
| 2024-12-31 | $892.0K | +13.5% | 2026-03-31, Balance as of period end |
| 2023-12-31 | $786.0K | +4.1% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $754.9K | -36.3% | 2024-04-01, Balance as of period end |
| 2021-12-31 | $1.18M | +2.7% | 2023-03-27, Balance as of period end |
| 2020-12-31 | $1.15M | +8.1% | 2022-03-31, Balance as of period end |
| 2019-12-31 | $1.07M | +64.7% | 2021-03-29, Balance as of period end |
| 2018-12-31 | $647.7K | n/a | 2020-03-30, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Nexentis Technologies Inc. (NXTS) | 2025-12-31 | $4.67M | +424.1% |
| Quoin Pharmaceuticals Ltd. (QNRX) | 2025-12-31 | $7.27M | +11.8% |
| Evofem Biosciences, Inc. (EVFM) | 2025-12-31 | $89.71M | -0.6% |
| Jyong Biotech Ltd. (MENS) | 2025-12-31 | $45.68M | +6.5% |
| Abvc Biopharma, Inc. (ABVC) | 2025-12-31 | $7.76M | +13.9% |
| Annovis Bio, Inc. (ANVS) | 2025-12-31 | $4.23M | -8.4% |
| Galectin Therapeutics Inc (GALT) | 2025-12-31 | $145.73M | +20.9% |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $85.04M | +6.2% |
| Phio Pharmaceuticals Corp. (PHIO) | 2025-12-31 | $1.34M | +32.0% |
Compare NXTS, QNRX, EVFM, MENS side by side · Screen every company in Pharmaceutical Preparations ↗